Clinical Trial Update: Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease [Phase 2]

View source ↗

Summary

Phase 2 trial comparing MEM 1003 to placebo in patients with mild to moderate Alzheimer's disease reports safety findings and signals of efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• MEM 1003

Snippet

Sponsor: Memory Pharmaceuticals | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED